Kerrisdale Advisers’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Kerrisdale Advisers’s Portfolio TARO Stock Details TARO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-27,615	Closed	-$3.96M	–	42
2016 Q1	$3.96M	Sell	27,615 -54,381	-66%	-$7.72M	0.68%	32
2015 Q4	$12.7M	Buy	81,996 +4,956	+6%	+$724K	3.24%	11
2015 Q3	$11M	Buy	+77,040	New	+$10.8M	3.2%	15

Other funds holding TARO

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MICM

Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return

Kerrisdale Advisers's TARO Position: Q2 2016 in Review

Kerrisdale Advisers sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q2 2016, closing a stake of 27,615 shares — an estimated $3.96M sold.

Kerrisdale Advisers first reported a position in TARO in Q3 2015 and held it in 3 quarters. The position peaked at $12.7M in Q4 2015. 159 funds tracked by Wall St. Rank hold TARO as of Q2 2016.

Kerrisdale Advisers reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q2 2016 after selling out during the quarter.
Kerrisdale Advisers sold 27,615 Taro Pharmaceutical Industries Ltd. shares in Q2 2016, an estimated $3.96M.
Kerrisdale Advisers first reported a position in Taro Pharmaceutical Industries Ltd. in Q3 2015 and held it in 3 quarters.
Kerrisdale Advisers's Taro Pharmaceutical Industries Ltd. position peaked at $12.7M in Q4 2015.
159 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q2 2016.

Based on Kerrisdale Advisers's 13F filing for Q2 2016, filed 12 Aug 2016.